Search
for
Sort by
Research 30 of 1000+
- The Alopecia Areata Severity and Morbidity Index (ASAMI) Study
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- Assessment of Alopecia Areata Disease Severity in Pediatric Patients
- Assessment of prognostic markers of alopecia areata in pediatric patients
- Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control
- Complete Blood Collection-based Systemic Inflammation Biomarkers as a Severity Biomarker in Alopecia Areata: A Cross-sectional Study
- Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
- 15. Hair and Nails
- Assessment of Interleukin-17A and Interleukin-2 Serum Levels in Patients with Alopecia Areata
- Skin
- VITAMIN D DEFICIENCY IN PATIENTS WITH ALOPECIA AERATA, AND RESPONSIVENESS TO VITAMIN D ANALOGUES: A SYSTEMATIC REVIEW
- Clinical and anamnestic features of alopecia areata in ukrainian men
- Serum IL-21 Level and Its Relation to Activity and Severity of Alopecia Areata
- Oxidative Stress in Alopecia Areata and its Association with Disease Severity, Treatment and Autoimmunity
- Quality of Life in Patients with Alopecia Areata presenting to the Department of Dermatology at a Tertiary Care Hospital of Lahore, Pakistan
- Efficacy, safety and dose response of STS01, a topical controlled release nanoparticle formulation (dithranol/Prosilic), in adults with mild to moderate patchy alopecia areata: A randomised, double-blind, multicentre, phase 2 trial
- Evaluation of Quality of Life, Anxiety and Depression in Patients with Alopecia Areata: A Prospective Case-Control Study
- Components of Severity in Alopecia Areata
- Impacto del desequilibrio del microbioma del cuero cabelludo en la severidad de la alopecia areata, marcadores inflamatorios y cambios post-tratamiento
- Chemokine C-C Motif Ligand 7 (CCL7), a Biomarker of Atherosclerosis, Is Associated with the Severity of Alopecia Areata: A Preliminary Study
- Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Estimation of health utility values for alopecia areata
- Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
- ‘The psychosocial burden of alopecia areata and androgenetica’: a cross‐sectional multicentre study among dermatological out‐patients in 13 European countries
- Depression among Alopecia Areata Patients: Prevalence and associated factors in a Tunisian sample
- Psychological burden of alopecia areata in patients with cancer: A narrative review
- Expert consensus on systemic treatment activation and grading evaluation for alopecia areata
- Psychosocial burden and the impact of illness perceptions and stigma on quality of life, anxiety and depression in alopecia areata: results from the Alopecia + Me study
- Biomarkers in alopecia Areata: A systematic review and meta-analysis.